Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Squamous Cell Carcinoma of Head and Neck 6Head and Neck Neoplasms 6Lung Neoplasms 4Neoplasm Metastasis 3Melanoma 3Skin Neoplasms 2Recurrence 2Cholangiocarcinoma 2Advanced Solid Tumor 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Squamous NSCLC 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Nonsquamous Non-small Cell Lung Cancer 1Neoplasms, Squamous Cell 1Neoplasms 1Mouth Neoplasms 1Mesothelioma 1Liver Neoplasms 1Laryngeal Neoplasms 1Laryngeal Diseases 1Klatskin Tumor 1Kidney Neoplasms 1Hypopharyngeal Neoplasms 1Hodgkin Disease 1Hepatoblastoma 1

Interventions

pembrolizumab 1HLX07 1Carboplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Squamous NSCLC × pembrolizumab × Clear all
NCT07318883 2026-01-06

A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer

Shanghai Henlius Biotech

Phase 2/3 Not yet recruiting
720 enrolled
Thoracic

Squamous NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡